Støy, Sidsel MD, PhD1; Laursen, Tea Lund MD, PhD1; Eriksen, Lotte Lindgreen MD1; Grønbæk, Henning MD, PhD1; Vilstrup, Hendrik MD, DMSc1; Sandahl, Thomas Damgaard MD, PhD1
doi : 10.14309/ctg.0000000000000306
February 2021 - Volume 12 - Issue 2 - p e00306
In alcoholic hepatitis (AH), translocation of gut bacteria may drive hepatic macrophage activation and systemic inflammation. We investigated the effect of oral non-absorbable, broad-spectrum antibiotic treatment on bacterial translocation and liver and systemic inflammation in AH.
Satapathy, Sanjaya K. MBBS, MD, DM, MS (Epi), FACG, FASGE, AGAF, FAASLD1,2,3; Tran, Quynh T. PhD4; Kovalic, Alexander J. MD5; Bontha, Sai Vineela PhD2; Jiang, Yu PhD6; Kedia, Satish PhD6; Karri, Saradashri MD3; Mupparaju, Vamsee MD2; Podila, Pradeep S. B. PhD, MHA, MS2; Verma, Rajanshu MD2,3; Maluf, Daniel MD2,3,7; Mas, Valeria PhD2; Nair, Satheesh MD2,3; Eason, James D. MD2,3; Bridges, Dave PhD8; Kleiner, David E. MD, PhD9
doi : 10.14309/ctg.0000000000000302
February 2021 - Volume 12 - Issue 2 - p e00302
Nonalcoholic fatty liver disease (NAFLD) has been increasingly reported among recipients of liver transplantation (LT). We aimed to identify clinical and genetic risk factors responsible for the development of early recurrent NAFLD in nonalcoholic steatohepatitis transplant recipients.
Lee, Hankil PhD1,2; Kim, Beom Kyung MD, PhD3,4,5; Jang, Sungin MD, PhD2,6; Ahn, Sang Hoon MD, PhD3,4,5
doi : 10.14309/ctg.0000000000000299
February 2021 - Volume 12 - Issue 2 - p e00299
Antiviral therapy (AVT) for chronic hepatitis B (CHB) can prevent liver disease progression. Because of its stringent reimbursement criteria, significant numbers of patients with untreated minimally active (UMA)-CHB exist, although they are still subject to disease progression. We thus performed a cost-effectiveness analysis to assess the rationale for AVT for UMA-CHB.
Kaewdech, Apichat MD1; Sripongpun, Pimsiri MD1; Cheewasereechon, Natcha MD1; Jandee, Sawangpong MD1; Chamroonkul, Naichaya MD1; Piratvisuth, Teerha MD1,2
doi : 10.14309/ctg.0000000000000310
February 2021 - Volume 12 - Issue 2 - p e00310
The “six-and-twelve” prognostic score was proposed recently to predict survival rate in patients with unresectable hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE). However, it has not been validated externally. We validated this score and previous prognostic scores in Thai HCC patients treated with TACE.
Yeh, Jen-Hao MD1,2,3; Lin, Chih-Wen MD, PhD1,3,4; Wang, Wen-Lun MD, PhD3,4; Lee, Ching-Tai MD3,4; Chen, Jen-Chieh MD1,5; Hsu, Chia-Chang MD3,5; Wang, Jaw-Yuan MD, PhD6,7,8,9
doi : 10.14309/ctg.0000000000000305
February 2021 - Volume 12 - Issue 2 - p e00305
The incidence of early-onset colorectal cancer is increasing. This study explored the feasibility of fecal immunochemical test (FIT) and risk factors for predicting colorectal neoplasm in younger adults.
Gargallo-Puyuelo, Carla J. MD, PhD1,2,3; Lanas, Ángel MD, PhD, DSc1,2,3,4; Carrera-Lasfuentes, Patricia PhD2; Ferrández, Ángel MD, PhD1,2; Quintero, Enrique MD, PhD5,6; Carrillo, Marta MD5; Alonso-Abreu, Inmaculada MD5; García-González, María Asunción MD, PhD2,4,7
doi : 10.14309/ctg.0000000000000301
February 2021 - Volume 12 - Issue 2 - p e00301
Epidemiological studies estimate that having a first-degree relative (FDR) with colorectal cancer (CRC) increases 2-fold to 3-fold the risk of developing the disease. Because FDRs of CRC patients are more likely to co-inherit CRC risk variants, we aimed to evaluate potential differences in genotype distribution of single nucleotide polymorphisms (SNPs) related to CRC risk between FDRs of patients with nonsyndromic CRC (cases) and individuals with no family history of CRC (controls).
Carot, Laura MD1,2,3; Navarro, Gemma PhD4; Naranjo-Hans, Dolores MD4; Iglesias-Coma, Mar MD, PhD4; Dalmases, Alba PhD4; Fernández, Lierni MS4; Seoane, Agustín MD1,3; Buron, Andrea MD, PhD3,5; Bellosillo, Beatriz MD, PhD2,4; Bessa, Xavier MD, PhD1,2,3; Andreu, Montserrat MD, PhD1,3; Alvarez-Urturi, Cristina MD, PhD1,3
doi : 10.14309/ctg.0000000000000304
February 2021 - Volume 12 - Issue 2 - p e00304
Guidelines for surveillance after polypectomy are lacking in strong evidence. Our aim was to identify some precursors of colorectal cancer lesions at 3 years after polypectomy to improve stratification and surveillance programs.
Idos, Gregory E. MD, MS1; Bonner, Joseph D. PhD1; Haghighat, Shida MD, MPH2; Gainey, Christina MD2; Shen, Stacy MD2; Mulgonkar, Ashwini MD2; Otero, Karla Joyce MSN3; Geronimo, Christine MSN3; Hurtado, Maria MSN3; Myers, Caitlin MSN3; Morales-Pichardo, Jennifer MS1; Kahana, Doron D. MD3,4; Giboney, Paul MD3; Dea, Stanley MD3
doi : 10.14309/ctg.0000000000000307
February 2021 - Volume 12 - Issue 2 - p e00307
Recent studies indicate low rates of follow-up colonoscopy after abnormal fecal immunochemical testing (FIT) within safety net health systems. A patient navigation (PN) program is an evidence-based strategy that has been shown to improve colonoscopy completion in private and public healthcare settings. The aim of this study was to evaluate the effectiveness of a PN program to encourage follow-up colonoscopy after abnormal FIT within a large safety net hospital system.
Bravo, Francisco MD1,2; Macpherson, Jamie A.1; Slack, Emma PhD1; Patuto, Nicolas MD2; Cahenzli, Julia PhD1; McCoy, Kathy D. PhD1; Macpherson, Andrew J. MD, PhD1,2; Juillerat, Pascal MD, MSc1,2; for the SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group
doi : 10.14309/ctg.0000000000000298
February 2021 - Volume 12 - Issue 2 - p e00298
The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNF? agent infliximab (IFX).
Ministro, Paula MD1; Dias, Cláudia Camila PhD2,3; Portela, Francisco MD4; Fernandes, Samuel MD5; Bernardo, Sónia MD5; Pires, Francisco MD1; Lago, Paula MD6; Rosa, Isadora MD7; Trindade, Eunice MD8; Alves, Catarina BSc9; Correia, Luís MD5; Magro, Fernando MD, PhD10,11,12,13
doi : 10.14309/ctg.0000000000000309
February 2021 - Volume 12 - Issue 2 - p e00309
Patients with elderly-onset inflammatory bowel disease were previously associated with a less aggressive course of the disease. However, there are conflicting data that need further validation. We aimed to determine the association between age at diagnosis and the development of progressive disease in patients with Crohn's disease (CD) and ulcerative colitis (UC).
Chiyanika, Chileka BSc, PgD, MSc1; Wong, Vincent Wai-Sun MBChB, MD, FRCP, FHKAM, FHKCP2,3; Wong, Grace Lai-Hung MBChB, MD, FRCP, FHKCP, FHKAM2,3; Chan, Henry Lik-Yuen MBChB, MD, FRCP, FHKCP, FHKAM2,3; Hui, Steve C. N. BSc, MSc, PhD4; Yeung, David K. W. BSc, MSc, PhD1,5; Chu, Winnie C. W. MBChB, MD, FRCR, FHKAM1
doi : 10.14309/ctg.0000000000000300
February 2021 - Volume 12 - Issue 2 - p e00300
Visceral adipose tissue (VAT) has been found to play a critical role in the development of metabolic syndrome and nonalcoholic fatty liver disease (NAFLD) independent of generalized obesity.
Dieterich, Walburga PhD1,2; Tietz, Esther MSc1,2; Kohl, Matthias PhD3; Konturek, Peter C. MD4; Rath, Timo MD1; Neurath, Markus F. MD1; Zopf, Yurdagül MD1,2
doi : 10.14309/ctg.0000000000000312
February 2021 - Volume 12 - Issue 2 - p e00312
The prevalence of patients with food intolerance (FI) has increased significantly. Immunoglobulin (Ig)E-mediated food allergies (FAs) are detected by determining IgE antibodies and skin prick test. Carbohydrate malabsorptions are clarified with breath tests. However, these diagnostic measures cannot capture all intolerances and have limitations in case of gut-mediated FI. The aims of this pilot study were to evaluate different methods to determine intestinal mucosal IgE in patients with FA and to characterize the intestinal mucosa in patients with FI of unknown origin (FH).
Cibert-Goton, Vincent PhD1; Lam, Ching PhD, MRCP2; Lingaya, Melanie BSci2; Falcone, Yirga BSci2; Wood, John N. FMedSci, FRS3; Bulmer, David C. PhD1,4; Spiller, Robin MD, FRCP2
doi : 10.14309/ctg.0000000000000313
February 2021 - Volume 12 - Issue 2 - p e00313
Despite heterogeneity, an increased prevalence of psychological comorbidity and an altered pronociceptive gut microenvironment have repeatedly emerged as causative pathophysiology in patients with irritable bowel syndrome (IBS). Our aim was to study these phenomena by comparing gut-related symptoms, psychological scores, and biopsy samples generated from a detailed diarrhea-predominant IBS patient (IBS-D) cohort before their entry into a previously reported clinical trial.
Gao, Yuan MM1; Xie, Jia NP1; Ye, Lian-Song MD1; Du, Jiang NP2; Zhang, Qiong-Ying NP1,2; Hu, Bing MD1,2
doi : 10.14309/ctg.0000000000000314
February 2021 - Volume 12 - Issue 2 - p e00314
During the coronavirus disease 2019 (COVID-19) pandemic, endoscopists have high risks of exposure to exhaled air from patients during gastroscopy. To minimize this risk, we transformed the oxygen mask into a fully closed negative-pressure gastroscope isolation mask. This study aimed to evaluate the effectiveness, safety, and feasibility of use of this mask during gastroscopy.
Raphael, Kara L. MD1; Inamdar, Sumant MBBS2; McKinley, Matthew J. MD1; Martinez, Nichol MD1; Cavaliere, Kimberly MD1; Kahn, Allon MD3; Leggett, Cadman L. MD4; Iyer, Prasad MD4; Wang, Kenneth K. MD4; Trindade, Arvind J. MD1
doi : 10.14309/ctg.0000000000000311
February 2021 - Volume 12 - Issue 2 - p e00311
Studies have shown that dysplasia in Barrett's esophagus (BE) has a predilection for the right hemisphere. There is limited information on the longitudinal distribution. The aim was to determine both the longitudinal and circumferential distributions of dysplasia and early neoplasia from 3 prospective studies.
Wang, An-Jiang MD, PhD; Zheng, Xue-Lian; Hong, Jun-Bo MD, PhD; Zhong, Jia-Wei MD; Yu, Hui-Qiang PhD; Zeng, Hai-Ying; Gong, Yue; Gan, Na; Wang, Jian MD; You, Yu MD, PhD; Guo, Gui-Hai MD; Xie, Bu-Shan MD, PhD; Li, Bi-Min MD, PhD; Zhu, Xuan MD
doi : 10.14309/ctg.0000000000000318
February 2021 - Volume 12 - Issue 2 - p e00318
Do you want to add Medilib to your home screen?